Clinical implications of drug interactions with coxibs

Pharmacotherapy

Volumn 21, Issue 10 I, 2001, Pages 1223-1232

  Garnett, W R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CAFFEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIGOXIN; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ION EXCHANGE RESIN; LITHIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PHENAZONE; PROBENECID; PROSTACYCLIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; STEROID; SUCRALFATE; THEOPHYLLINE; THROMBOXANE A2; UNINDEXED DRUG; ZIDOVUDINE;

DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HEMOSTASIS; HUMAN; LIVER METABOLISM; PATIENT MONITORING; PROSTAGLANDIN METABOLISM; REVIEW;

EID: 0034791164     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.15.1223.33891     Document Type: Review

References (63)

1. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs
2. NSAIDs and the elderly: Toxicity and economic implications
3. Drug interactions in arthritis patients
4. New insights into the mode of action of anti-inflammatory drugs
5. Cyclooxygenase in biology and disease
6. COX-1 and COX-2 tissue expression: Implications and predictions
7. Role and regulation of cyclooxygenase-2 during inflammation
8. Role of cyclooxygenase-1 and -2 in health and disease
9. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
10. NSAID adverse effects and interactions: Who is at risk?
11. COX-2 inhibitors
12. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
13. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
14. Sc-58635 (celecoxib): A highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP 450 isozyme in its biotransformation
15. Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 [MK], on cytochrome P50 [CYP] activity
16. Update: Clinically significant cytochrome P-450 drug interactions
17. Recent advances: The cytochrome P450 enzymes
18. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics
19. Role of the cytochrome P450 3A subfamily in drug interactions
20. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYPC9 in a Japanese population
21. Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism
22. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily
23. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu- variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes
24. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population
25. Genetic polymorphisms of the CYP2C subfamily
26. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
27. Celecoxib for arthritis
28. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
29. Update on rifampin drug interactions. III
30. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome p450IIIA induction
31. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
32. Rifampin drastically reduces plasma concentrations and effects of oral midazolam
33. Theophylline N-demethylations as probes for P4501A1 and P4501A2
34. Characterization of human liver cytochromes P-450 involved in theophylline metabolism
35. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin
36. Influence of a selective cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, on prednisone and prednisolone plasma concentrations
37. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis
38. Effect of aspirin and sulindac on methotrexate clearance
39. Comparison of toxicity in methotrexate (MTX) treated RA patients also taking aspirin or other NSAIDs
40. Lack of significant interaction between low dose methotrexate and ibuprofen in patients with arthritis
41. Drug-drug interactions with antirheumatic agents: Review of selected clinically important interactions
42. Rofecoxib up to 50 mg daily did not affect methotrexate plasma concentrations
43. Guidelines for monitoring drug therapy in rheumatoid arthritis
44. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin, two medications commonly used by arthritis patients
45. Influence of antacids on the bioavailability of a specific cyclooxygenase (COX)-2 inhibitor, MK-0966 (rofecoxib, VIOXX), in the elderly
46. Influence of a selective cyclooxygenase-2 inhibitor, MK-0966, on ethinyl estradiol (EE) and norethindrone (NET) serum concentrations
47. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
48. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity
49. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly
50. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX-2 inhibitors
51. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 in healthy volunteers
52. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
53. Arachidonate metabolism in vascular disorders
54. 2) production and platelet aggregation
55. Adverse interactions between warfarin and nonsteroidal anti-inflammatory drugs: Mechanisms, clinical significance, and avoidance
56. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects
57. Interaction of antihypertensive drugs with anti-inflammatory drugs
58. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
59. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure
60. Nonsteroidal anti-inflammatory drugs and antihypertensives